Literature DB >> 2419266

Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV).

J Balzarini, H Mitsuya, E De Clercq, S Broder.   

Abstract

Suramin and various other selected compounds were evaluated for their in vitro inhibitory effects on the infectivity and replication of human T-cell lymphotropic virus (HTLV/III)/lymphadenopathy-associated virus (LAV). As parameters for infectivity and replication, respectively, we followed the cytopathic effect of HTLV-III/LAV on ATH 8 cells, a T-cell clone with high susceptibility to HTLV-III/LAV, and the expression of HTLV-III/LAV p24 gag protein in H9 cells infected with HTLV-III/LAV. As the most effective inhibitors of HTLV-III/LAV the following substances emerged (in order of decreasing activity): Evans Blue approximately equal to suramin greater than phosphonoformic acid greater than Direct Yellow 50. Several purine nucleoside analogues including vidarabine, tubercidin, neplanocin A, dihydroxypropyladenine, pyrazofurin and ribavirin were not inhibitory to HTLV-III/LAV. In our test systems, involving a high multiplicity of infection, HPA-23, previously reported to be effective against LAV reverse transcriptase, showed no inhibitory effect on HTLV-III/LAV infectivity for ATH 8 cells and proved only weakly inhibitory to HTLV-III/LAV replication in H9 cells. Thus, among the anionic dyes that are structurally related to suramin, compounds were found which were as active as suramin itself, if not more so.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419266     DOI: 10.1002/ijc.2910370318

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Anti-HIV-1 efficacy of extracts from medicinal plants.

Authors:  Su-A Lee; Seong-Karp Hong; Chang-Il Suh; Mi-Hwa Oh; Jeong-Ho Park; Byoung-Wook Choi; Seung-Won Park; Soon-Young Paik
Journal:  J Microbiol       Date:  2010-05-01       Impact factor: 3.422

Review 2.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro.

Authors:  J Balzarini; D Schols; J Neyts; E Van Damme; W Peumans; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent.

Authors:  J Balzarini; L Naesens; P Herdewijn; I Rosenberg; A Holy; R Pauwels; M Baba; D G Johns; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

5.  The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels.

Authors:  R C Tam; K Ramasamy; J Bard; B Pai; C Lim; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides.

Authors:  K B Frank; P A McKernan; R A Smith; D F Smee
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

7.  Specific inhibition of the DNA-anti-DNA immune reaction by low molecular weight anionic compounds.

Authors:  E Ben-Chetrit; D Eilat; S A Ben-Sasson
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

Review 8.  Treatment of human immunodeficiency virus infections.

Authors:  M S Hirsch; J C Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

9.  Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever.

Authors:  Brian B Gowen; Justin G Julander; Nyall R London; Min-Hui Wong; Deanna Larson; John D Morrey; Dean Y Li; Mike Bray
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

Review 10.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.